News
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Despite the Trump administration’s efforts to shrink the FDA, Senate appropriators unanimously advanced a funding bill ...
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results